Altasciences' comprehensive, integrated solution for clinical supply manufacture

Bio Pharma Dive

Integrated CRO/CDMO solutions for accelerated and more efficient early drug development programs

[Webinar] How biotech companies can improve clinical supply planning and distrib…

The Pharma Data

Find out solutions to mitigate the impact from clinical supply chain risk and discover how to improve dynamic drug supply forecasting strategies. Enrolling study subjects, setting up patient randomization and managing drug supply are critical to the success of a clinical trial.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

PCI Pharma Services Announces Global Expansion of Clinical Trial Services

Journal for Clinical Studies

PCI Broadens Global Clinical Supply-Chain Service Offerings Into Mainland Europe PHILADELPHIA – July 28, 2020 – PCI Pharma Services (PCI),… Europe Regional News

GCSG 2020 Virtual Conference

Client Pharma

Client-Pharma is proud to be a Bronze sponsor at this year’s first-ever Global Clinical Supplies Group – GCSG 2020 Virtual Conference. Join us and other professionals September 21-25 for interactive and engaging workshop discussions, developing best practices in clinical trial supply and fun networking events from the comfort of your home or office.

How to plan for uncertainty while maximizing the efficiency of your clinical sup…

The Pharma Data

Supply chain uncertainty is a challenge every clinical supply chain manager wrestles with – stemming from increasing product demand and quality, the growing complexity of clinical trial designs and a lack of visibility in the supply chain. Clinical Trails

How direct-to-patient clinical trial models can accelerate speed-to-market

The Pharma Data

Analyzing the benefits and challenges of implementing direct-to-patient services in the clinical supply chain to help meet patient requirements, improve supply chain efficiency and accelerate speed to market.

Oxford Biomedica and Beam Therapeutics sign CAR-T deal

The Pharma Data

The agreement also puts in place a three year clinical supply agreement for the two companies. Agreement will utilise Oxford Biomedica's LentiVector platform.

Keeping tabs on Covid-19: BioNTech buys GMP-certified facility to boost vaccine…

The Pharma Data

The BNT162 program includes five mRNA vaccine candidates currently in clinical testing in the US, Europe, South America and China. has partnered with OmeCare, a CLIA-certified global clinical laboratory provider, to launch a new diagnostic test solution for Covid-19. Clinical Trails

MorphoSys To Present At the 39th Annual J.P. Morgan Healthcare Conference

The Pharma Data

Based on its leading expertise in antibody, protein and peptide technologies, MorphoSys, together with its partners, has developed and contributed to the development of more than 100 product candidates, of which 27 are currently in clinical development.

PharmaDrug Enters Definitive Agreement for Acquisition of Sairiyo Therapeutics Inc. Who Recently Received Orphan Drug Designation from FDA for Esophageal Cancer

The Pharma Data

Sairiyo is advancing the clinical development of its lead drug candidate, Cepharanthine, a repurposed and reformulated naturally derived compound for the potential treatment of cancer, neurological, inflammatory and infectious diseases. Toronto, Ontario–(Newsfile Corp.

Molecular Partners Doses First Cohort in Phase 1 Trial of COVID-19 DARPin(R) Therapeutic Candidate MP0420

The Pharma Data

ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / November 23, 2020 / Molecular Partners AG (SIX:MOLN), a clinical-stage biotech company that is developing a new class of custom-built protein drugs known as DARPin® therapeutics, today announced that a first cohort of eight healthy volunteers has been dosed in a Phase 1 first-in-human study of MP0420 (ensovibep), a DARPin® therapeutic candidate for the potential treatment and prevention of COVID-19.

Nordic Nanovector ASA: Results for the Third Quarter 2020

The Pharma Data

Lars Nieba, Interim CEO of Nordic Nanovector, said: “Following the successful interim analysis in August and completion of our private placement in September, we are progressing towards the major value inflection point of three-month top-line data from the PARADIGME clinical study, which is targeted for H2 2021. In addition, travel restrictions could create logistical challenges for the shipment of clinical supplies. OSLO, Norway , Nov.

Molecular Partners Announces Collaboration With Novartis to Develop Two DARPin(R) Therapies Designed for Potential Use Against COVID-19

The Pharma Data

During the clinical development stage, Molecular Partners will provide clinical supply. The companies will work together to scale-up manufacturing capacity, in collaboration with Sandoz, the generics and biosimilar Novartis division, to provide worldwide supply.